Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Kim Harrow"'
Autor:
Chris Liang, V. Oertel, Ziping Wang, Yun Fan, Leora Horn, Ying Cheng, Elena Poddubskaya, Yi Zhou, Tony Mok, Li Mao, Giovanni Selvaggi, Alberto Chiappori, Irfan Cicin, Gang Wu, Heather A. Wakelee, Dae Ho Lee, Valeriy Breder, Yunpeng Liu, Jennifer G. Whisenant, Yi-Long Wu, Kim Harrow, Sergey Orlov, Martin Reck
Publikováno v:
JAMA Oncology. 7:1617
Ensartinib, an oral tyrosine kinase inhibitor of anaplastic lymphoma kinase (ALK), has shown systemic and central nervous system efficacy for patients with ALK-positive non-small cell lung cancer (NSCLC).To compare ensartinib with crizotinib among pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96aae27c75e7c07628a4d8e28a2f94ac
https://doi.org/10.1001/jamaoncol.2021.3523
https://doi.org/10.1001/jamaoncol.2021.3523
Autor:
Kim Harrow, Jill M. Kolesar, Kimberly Binger, Glenn Liu, Jens C. Eickhoff, Murtuza Rampurwala, Lakeesha Carmichael, Chris Liang, Justine Yang Bruce, Scott B. Perlman, Robert Jeraj, Jennifer Heideman, Matthew Scarpelli, Gary Dukart
Publikováno v:
Cancer Chemother Pharmacol
BACKGROUND: A sequential approach, synchronizing cell-cycle specific chemotherapy during VEGFR-TKI treatment breaks, may improve the therapeutic index of this combination therapy. In this study we investigate the safety/tolerability and pharmacodynam
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57332446c6622421810c3dc903b1d769
https://doi.org/10.1200/jco.2015.33.15_suppl.tps2601
https://doi.org/10.1200/jco.2015.33.15_suppl.tps2601